GET DAILY SIGNALSProtalix BioTherapeutics (PLX) Delivers Strong Q3 Results on Elfabrio Momentum
Key Takeaways
- Third-quarter 2026 total revenue reached $21.9 million, up from $17.9 million in the prior-year period.
- Net income came in at $4.0 million, or $0.05 per share (basic and diluted), versus $2.4 million, or $0.03 per share, a year earlier.
- Results comfortably beat consensus, which had projected a loss of $0.02 per share on roughly $12.4 million in revenue.
- Revenue from selling goods rose to $21.8 million, driven mainly by higher Elfabrio sales to partner Chiesi.
- Cash, cash equivalents, and short-term bank deposits totaled $48.5 million as of September 30, 2026, with no outstanding debt or warrants.
- Management reaffirmed its full-year 2026 revenue guidance of approximately $78 million to $83 million and expects to meet or exceed that range.
- For more detail, explore Protalix BioTherapeutics' Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Discover new trading ideas with Trending AI Robots to help you track market opportunities more efficiently.
Why These Results Matter
Protalix BioTherapeutics (PLX) relies on its proprietary ProCellEx plant cell-based protein expression system and currently markets two therapies: Elfabrio for Fabry disease and Elelyso for Gaucher disease. The third-quarter numbers provide an important test of whether product sales can sustain profitability on their own, following the $25 million Chiesi milestone received earlier in 2026. The every-four-weeks dosing approval for Elfabrio in the European Union during March 2026 appears to have supported stronger demand, which is encouraging for the longer-term commercial outlook.
Breaking Down the Quarter
Total revenue for the third quarter of 2026 came in at $21.9 million, compared with $17.9 million a year earlier. Revenue from selling goods reached $21.8 million, up from $17.7 million, primarily reflecting increased Elfabrio shipments to Chiesi. License and R&D services contributed a modest $0.1 million.
Net income totaled $4.0 million, or $0.05 per share basic and diluted, versus $2.4 million, or $0.03 per share, in the same quarter of 2025. The outcome exceeded analyst expectations, which had pointed to a $0.02 per share loss on roughly $12.4 million in revenue. Cost of revenues fell to $7.9 million from $8.3 million, while R&D expenses rose to $6.9 million from $4.5 million, mainly due to costs associated with the Phase 2 RELEASE study of PRX-115. SG&A expenses moved slightly higher to $3.1 million. Management reiterated full-year 2026 revenue guidance of approximately $78 million to $83 million and indicated it expects to meet or exceed the range.
Market Reaction and What Investors Are Watching
The results came in well ahead of consensus, with profitability achieved in a period where analysts had modeled a modest loss. The improvement stemmed largely from product sales rather than one-time milestones, which suggests the Elfabrio franchise is gaining traction. Comments from the earnings call highlighted accelerated patient uptake in Europe following the dosing approval, pointing to more durable revenue growth. Pipeline timing remains a focus, as Phase 2 enrollment for PRX-115 may shift slightly into the next quarter.
Looking Ahead
Attention now turns to whether Elfabrio sales momentum carries into 2027, with management planning to issue formal guidance alongside full-year results. The recent improvement in gross margins, tied to a greater share of higher-margin Chiesi sales, will be worth monitoring. Longer term, PRX-115 for uncontrolled gout remains the key catalyst, with Phase 2 top-line data still expected in the second half of 2027. Investors will also track R&D spending trends and the company's cash position, which stood at $48.5 million with no debt or warrants at the end of September.
Refining My Research Process
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. As part of my ongoing research, I regularly use Tickeron’s AI Screener to filter for comparable names, review technical patterns, and quickly surface relevant ideas across sectors. It helps streamline the process of validating trends without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for PLX turns positive, indicating new upward trend
PLX saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 76 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 58 cases where PLX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for PLX just turned positive on November 10, 2026. Looking at past instances where PLX's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
PLX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLX advanced for three days, in 207 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The 10-day moving average for PLX crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
PLX broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PLX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 32 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 58 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.866) is normal, around the industry mean (3.498). P/E Ratio (10.583) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.697) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant therapeutic proteins
Industry Biotechnology
Advertisement